Early Renin Recovery After Adrenalectomy in Aldosterone-Producing Adenomas: A Prospective Study

Abstract

The aim of the study was to clarify the relationship and the time of aldosterone and renin recoveries at immediate and long-term follow-up in aldosterone-producing adenoma (APA) patients who underwent adrenalectomy. Prospective and longitudinal protocol in a cohort of APA patients was followed in a single center. Among 43 patients with primary aldosteronism (PA), thirteen APA patients were enrolled in this study. Blood was collected for aldosterone, renin, potassium, creatinine, cortisol, and ACTH before and 1, 3, 5, 7, 15, 30, 60, 90, 120, 180, 270, 360 days after adrenalectomy. At diagnosis, most patients (84%) had hypokalemia and high median aldosterone levels (54.8; 24.0–103 ng/dl) that decreased to undetectable (<2.2) or very low (<3.0) levels between fifth to seventh days after surgery; then, between 3–12 months, its levels gradually increased to the lower normal range. The suppressed renin (2.3; 2.3–2.3 mU/l) became detectable between the fifteen and thirty days after surgery, remaining normal throughout the study. The aldosterone took longer than renin to recover (60 vs.15 days; p<0.002) and patients with higher aldosterone had later recovery (p=0.03). The cortisol/ACTH levels remained normal despite the presence of a post-operative hypoaldosteronism. Blood pressure and antihypertensive requirement decreased after adrenalectomy. In conclusion, our prospective study shows the borderline persistent post-operative hypoaldosteronism in the presence of early renin recovery indicating incapability of the zona glomerulosa of the remaining adrenal gland to produce aldosterone. These findings contribute to the comprehension of differences in renin and aldosterone regulation in APA patients, although both are part of the same interconnected system.

Key words

renin-aldosterone relationship - primary aldosteronism - APA - adrenalectomy

Publikationsverlauf

Eingereicht: 25. November 2021

Angenommen: 09. Februar 2022

Artikel online veröffentlicht:
12. April 2022

• References

• 1 Young WF. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med 2019; 285: 126-148
• 2 Brown JM, Siddiqui M, Calhoun DA. et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med 2020; 173: 10-20
• 3 Käyser SC, Dekkers T, Groenewoud HJ. et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab 2016; 101: 2826-2835
• 4 Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17
• 5 Rossi GP, Bernini G, Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300
• 6 Yozamp N, Vaidya A. The prevalence of primary aldosteronism and evolving approaches for treatment. Curr Opin Endocr Metab Res 2019; 8: 30-39
• 7 Zennaro MC, Boulkroun S, Fernandes-Rosa FL. Pathogenesis and treatment of primary aldosteronism. Nat Rev Endocrinol 2020; 16: 578-589
• 8 Funder JW, Carey RM, Fardella C. et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281
• 9 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
• 10 Williams TA, Reincke M. Management of endocrine disease: diagnosis and management of primary aldosteronism: the endocrine society guideline 2016 revisited. Eur J Endocrinol 2018; 179: R19-R29
• 11 Williams TA, Lenders JWM, Mulatero P. et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017; 5: 689-699
• 12 Miller BS, Turcu AF, Nanba AT. et al. Refining the definitions of biochemical and clinical cure for primary aldosteronism using the primary aldosteronism surgical outcome (PASO) classification system. World J Surg 2018; 42: 453-463
• 13 Vorselaars WMCM, van Beek DJ, Postma EL. et al. Clinical outcomes after surgery for primary aldosteronism: Evaluation of the PASO-investigators’ consensus criteria within a worldwide cohort of patients. Surgery 2019; 166: 61-68
• 14 Burrello J, Burrello A, Stowasser M. et al. The primary aldosteronism surgical outcome score for the prediction of clinical outcomes after adrenalectomy for unilateral primary aldosteronism. Ann Surg 2020; 272: 1125-1132
• 15 Taniguchi R, Koshiyama H, Yamauchi M. et al. A case of aldosterone-producing adenoma with severe postoperative hyperkalemia. Tohoku J Exp Med 1998; 186: 215-223
• 16 Shariq OA, Bancos I, Cronin PA. et al. Contralateral suppression of aldosterone at adrenal venous sampling predicts hyperkalemia following adrenalectomy for primary aldosteronism. Surgery 2018; 163: 183-190
• 17 Fischer E, Hanslik G, Pallauf A. et al. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy. J Clin Endocrinol Metab 2012; 97: 3965-3973
• 18 Huang WT, Chau T, Wu ST. et al. Prolonged hyperkalemia following unilateral adrenalectomy for primary hyperaldosteronism. Clin Nephrol 2010; 73: 392-397
• 19 Yorke E, Stafford S, Holmes D. et al. Aldosterone deficiency after unilateral adrenalectomy for Conn's syndrome: a case report and literature review. Int J Surg Case Rep 2015; 7C: 141-144
• 20 Tahir A, McLaughlin K, Kline G. Severe hyperkalemia following adrenalectomy for aldosteronoma: prediction, pathogenesis and approach to clinical management – a case series. BMC Endocr Disord 2016; 16: 43
• 21 Kanarek-Kucner J, Stefański A, Barraclough R. et al. Insufficiency of the zona glomerulosa of the adrenal cortex and progressive kidney insufficiency following unilateral adrenalectomy – case report and discussion. Blood Press 2018; 27: 304-312
• 22 Preda C, Teodoriu LC, Placinta S. et al. Persistent severe hyperkalemia following surgical treatment of aldosterone-producing adenoma. J Res Med Sci 2020; 25: 17
• 23 Park KS, Kim JH, Ku EJ. et al. Clinical risk factors of postoperative hyperkalemia after adrenalectomy in patients with aldosterone-producing adenoma. Eur J Endocrinol 2015; 172: 725-731
• 24 Biglieri EG, Slaton PE, Silen WS. et al. Postoperative studies of adrenal function in primary aldosteronism. J Clin Endocrinol Metab 1966; 26: 553-558
• 25 Bravo EL, Dustan HP, Tarazi RC. Selective hypoaldosteronism despite prolonged pre- and postoperative hyperreninemia in primary aldosteronism. J Clin Endocrinol Metab 1975; 41: 611-617
• 26 Gordon RD, Hawkins PG, Hamlet SM. et al. Reduced adrenal secretory mass after unilateral adrenalectomy for aldosterone-producing adenoma may explain unexpected incidence of hypotension. J Hypertens Suppl 1989; 7: S210-S211
• 27 Gadallah MF, Kayyas Y, Boules F. Reversible suppression of the renin-aldosterone axis after unilateral adrenalectomy for adrenal adenoma. Am J Kidney Dis 1998; 32: 160-163
• 28 Pasternak JD, Epelboym I, Seiser N. et al. Diagnostic utility of data from adrenal venous sampling for primary aldosteronism despite failed cannulation of the right adrenal vein. Surgery 2016; 159: 267-273
• 29 Arlt W, Lang K, Sitch AJ. et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight 2017; 2: e93136
• 30 Castro M, Moreira AC. Screening and diagnosis of Cushing’s syndrome. Arq Bras Endocrinol Metabol 2007; 51: 1191-1198
• 31 Fortunato A, Prontera C, Masotti S. et al. State of the art of aldosterone immunoassays. A multicenter collaborative study on the behalf of the Cardiovascular Biomarkers Study Group of the Italian Section of European Society of Ligand Assay (ELAS) and Società Italiana di Biochimica Clinica (SIBIOC). Clin Chim Acta 2015; 444: 106-112
• 32 Vilela LAP, Rassi-Cruz M, Guimaraes AG. et al. KCNJ5 somatic mutation is a predictor of hypertension remission after adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab 2019; 104: 4695-4702
• 33 Sparks MA, Crowley SD, Gurley SB. et al. Classical renin-angiotensin system in kidney physiology. Compr Physiol 2014; 4: 1201-1228
• 34 Graber AL, Ney RL, Nicholson WE. et al. Natural history of pituitry-adrenal recovery following long-term suppresion withcorticosteroids. J Clin Endocrinol Metab 1965; 25: 11-16
• 35 Di Dalmazi G, Berr CM, Fassnacht M. et al. Adrenal function after adrenalectomy for subclinical hypercortisolism and Cushing’s syndrome: a systematic review of the literature. J Clin Endocrinol Metab 2014; 99: 2637-2645
• 36 Bhatt PS, Sam AH, Meeran KM. et al. The relevance of cortisol co-secretion from aldosterone-producing adenomas. Hormones (Athens) 2019; 18: 307-313